SRF and systemic sclerosis: Usage of CCG-203971 (the MRTF/SRF inhibitor) inhibited those fibrosis markers in SSc-patient dermal fibroblasts and attenuated skin-thickening and collagen deposition in a bleomycin-induced skin injury murine model (Figures 6B, C) (96).